AviadoBio, a groundbreaking gene therapy company at the forefront of developing and delivering life-changing treatments for those suffering from neurodegenerative disorders, is proud to announce the appointment of Jeff Goater as Chair of its Board of Directors. With over two decades of experience in the biotech sector and a deep understanding of gene therapy, Mr. Goater is well-positioned to lead AviadoBio as it continues its mission to improve the lives of people around the world.
We are delighted to welcome Jeff to the team as he brings a wealth of expertise in biotechnology to our company. His exceptional track record of bringing innovative treatments to clinical development is an invaluable asset to us. Jeff’s scientific background will be invaluable in helping us explore the powerful potential of gene therapies to improve the lives of those living with neurodegenerative diseases. We are excited to work with him as we continue to develop our gene therapies and delivery systems for frontotemporal dementia and amyotrophic lateral sclerosis.
Mr. Goater is an esteemed Venture Partner at The Column Group and Interim CEO of Atavistik Bio. His impressive career includes a transformative tenure as CEO of Surface Oncology, where he fostered a highly-praised culture, drove four programs into clinical development, and took the company public, alongside securing several strategic collaborations, including a ground-breaking partnership with GlaxoSmithKline. Before this, Goater was Chief Financial Officer of Voyager Therapeutics and spent almost a decade in investment banking, culminating in a Managing Director role at Evercore Partners, where he played a fundamental role in more than $100 billion worth of biopharma strategic transactions.
Jeff Goater is passionate about the potential of gene therapy to radically improve the lives of individuals affected by neurodegenerative diseases. He is thrilled to join the AviadoBio team, which is dedicated to developing novel gene therapy approaches with the goal of targeting the root cause of frontotemporal dementia and amyotrophic lateral sclerosis.
Mr. Goater is an acclaimed research scientist in the field of AAV gene therapy, and he holds prestigious master’s degrees in microbiology/immunology, pathology, and business administration from the University of Rochester. He is currently an esteemed board member of Atavistik Bio, Judo Bio, Kallyope, Ribon Therapeutics, and Surface Oncology. With a wealth of knowledge and expertise, he is driving forward pioneering advancements in the field.
At AviadoBio, we are driven by a mission to bring potentially transformative gene therapies to those living with devastating neurodegenerative diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Our team is committed to finding solutions to the challenges of delivering the right drug to the right place. We have developed a groundbreaking neuroanatomy-led approach that is designed to maximize the therapeutic potential of gene therapy, giving us the potential to halt or even reverse the progression of these diseases.
AviadoBio is a revolutionary company with a leadership team that has unparalleled experience in gene therapy development, delivery, and commercialization. This combination of expertise, combined with pioneering research from King’s College London and the UK Dementia Research Institute, puts AviadoBio in a unique position to bring transformative medicines to patients in need.
AviadoBio has secured investment from some of the top names in the life sciences sector, including New Enterprise Associates (NEA), Monograph Capital, F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Dementia Discovery Fund (DDF), Advent Life Sciences, EQT Lifesciences, and LifeArc. The collective expertise of these investors will help to drive AviadoBio’s mission of improving health outcomes and creating innovative solutions for the life sciences community.